Trials / Completed
CompletedNCT00168389
A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 494 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone | 350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months. |
| OTHER | Sham | Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months. |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2005-09-15
- Last updated
- 2014-08-04
- Results posted
- 2014-08-04
Locations
10 sites across 10 countries: United States, Australia, Canada, Czechia, Germany, Israel, Philippines, Portugal, South Africa, Spain
Source: ClinicalTrials.gov record NCT00168389. Inclusion in this directory is not an endorsement.